Blog | HemaCare

Can TRuCs Beat CARs?

Jul 30, 2019 10:08:00 AM / by Nancy Andon, MSc posted in CAR-T, Immunotherapy, T Cells


Exciting new research published in Nature Communications cites using HemaCare leukapheresis material to design primary human T cells that may be more effective at fighting cancer than CAR-T cells. [1]

The successful treatment of B cell leukemias with genetically modified T cells heralded a new frontier in cell-based medicines. CAR-T cells, or chimeric antigen receptor T cells, have become the face of cell and gene therapy, with Novartis’ first-in-class Kymriah® prompting a robust pipeline of competitive CAR-T treatments. Now a research group in Cambridge, Massachusetts is taking T cell-based immunotherapy one step further. By changing the way T cells target cancer cells, they claim to have come up with a more effective cancer immunotherapy mechanism.

Read More

NK Cell Clinical Trial Begins for Incurable Cancer

Jul 16, 2019 10:12:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy, NK Cells


New tests begin in the United States using stem cell-derived natural killer cells to help patients suffering from incurable cancer.

Curing the incurable is an ongoing and top endeavor in medical research. This is particularly true for the various forms of cancer that are difficult to treat. The investigation and use of immunotherapy as an option for the treatment of different forms of cancer continues to increase. The main immunotherapeutic approach to cancer involves harvesting stem cells from the patient or a donor. Given the logistics, cost, and time this approach takes, the development of a strategy or cell products that can be used on demand is much desired.

Read More

Better Immunotherapy Research Needed for Elderly Lung Cancer Patients

Jun 25, 2019 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy


Varied responses to immunotherapy among elderly lung cancer patients reveal the need for more age-inclusive research and clinical trials.

The proportion of the U.S. population that is over 65 years of age has risen. Almost 50 million people are in this age range, a result of medical advancements which improve survival. However, cancer incidence has increased in this same age-group. More specifically, the 75 to 84-year-old age group has the highest percentage of cancer deaths. This increased incidence of cancer in the elderly may be associated with changes that occur in the immune system with advancing age.

Read More

Improving Immune Checkpoint Therapy for Melanoma

Apr 23, 2019 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cytotoxic T Cells, Immunotherapy, T Cells


Melanoma is the most serious form of skin cancer and more likely to grow and metastasize. It has a high response rate to checkpoint inhibitor therapy compared to other cancers; however, about 60% of patients treated do not respond well or relapse. Immune checkpoints are proteins expressed on T cells and function to ensure self-tolerance, but they are also used by tumor cells to limit anti-tumor immune function.

Read More

Cell Interactions for Immunotherapy and More

Feb 12, 2019 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Dendritic Cells, Immunotherapy, T Cells


“Kiss-and-run” approach helps researchers observe interaction between dendritic cells and T cells.

The normal biological processes needed for living beings to develop, grow, and function involve interactions between a diversity of cell types. Targeting these cellular interactions can enhance current cell-based immunotherapy and regenerative medicine, as well as provide the basis for new ones. Studying the mechanisms of these interactions is necessary in order to understand the means by which they affect cell signaling, immunity, growth and development, and more.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts